N-(4-chlorophenyl)piperidin-4-amine dihydrochloride | 99918-44-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(4-chlorophenyl)piperidin-4-amine dihydrochloride
• 英文别名: N-(4-chlorophenyl)piperidin-4-amine hydrochloride；N-(4-chlorophenyl)piperidin-4-amine;hydrochloride
• CAS: 99918-44-2
• 化学式: C₁₁H₁₅ClN₂*2ClH
• 分子量: 283.628
• InChiKey: YDTQFTDRFJMCCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.93
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  24.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氟苯腈 、 N-(4-chlorophenyl)piperidin-4-amine dihydrochloride 在 sodium hydroxide 、 三氯化硼 作用下， 生成 N-[4-chloro-2-(2-fluorobenzenecarboximidoyl)phenyl]piperidin-4-amine
  参考文献：
  名称：

  Adachi, Makoto; Sasakura, Kazuyuki; Sugasawa, Tsutomu, Chemical and pharmaceutical bulletin, 1985, vol. 33, # 5, p. 1826 - 1835

  摘要：

  DOI：
• 作为产物：
  描述：

  4-[(4-氯苯基)氨基]哌啶-1-羧酸乙酯 在 盐酸 作用下， 以 水 为溶剂， 反应 16.0h， 以92%的产率得到N-(4-chlorophenyl)piperidin-4-amine dihydrochloride
  参考文献：
  名称：

  Adachi, Makoto; Sasakura, Kazuyuki; Sugasawa, Tsutomu, Chemical and pharmaceutical bulletin, 1985, vol. 33, # 5, p. 1826 - 1835

  摘要：

  DOI：

文献信息

• [EN] QUINOXALINE DERIVATIVES AS GPR6 MODULATORS<br/>[FR] DÉRIVÉS DE QUINOXALINE EN TANT QUE MODULATEURS DU GPR6
  申请人：ENVOY THERAPEUTICS INC

  公开号：WO2014028479A1

  公开（公告）日：2014-02-20

  The present invention provides compounds of Formula (I) that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了式(I)化合物，该化合物是GPR6调节剂，因此可用于治疗可通过调节GPR6来治疗的疾病，特别是治疗帕金森病、左旋多巴诱导的舞蹈病、亨廷顿病、其他舞蹈病、运动不能、涉及纹状体功能障碍的运动障碍、精神分裂症和药物成瘾。还提供了含有此类化合物的药物组合物以及制备此类化合物的过程。
• SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150111922A1

  公开（公告）日：2015-04-23

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: (I) in which m, n, W, X, Y, Z, R 1 , R 2 , R 3 and R 4 are as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conditions.

  本发明提供了公式（I）的化合物及其药学上可接受的盐：（I）其中m、n、W、X、Y、Z、R1、R2、R3和R4如规范中所定义，用于治疗或预防由前动力素介导的疾病或情况，例如精神和神经疾病。
• THERAPEUTIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20130324576A1

  公开（公告）日：2013-12-05

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R 1 , R 2 , R 3 and R 4 are as defined in the specification, for use in therapy.

  本发明提供公式（I）的化合物及其药学上可接受的盐，其中m、n、W、X、Y、Z、R、R1、R2、R3和R4在规范中定义，用于治疗。
• ISOQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION, COMPRISING SAME AS ACTIVE INGREDIENT, FOR PREVENTION OR TREATMENT OF POLY(ADP-RIBOSE)POLYMERASE-1 (PARP-1)-ASSOCIATED DISEASE
  申请人：Digmbio. Inc.

  公开号：EP4053106A1

  公开（公告）日：2022-09-07

  The present invention relates to isoquinolinone derivatives, a method for preparing the same, and a pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1 (PARP-1)-related diseases containing the same as an active ingredient. The isoquinolinone derivatives exhibit an excellent PARP-1 inhibitory effect at a concentration of nanomolar units, and further exhibit an excellent cytoprotective effect (apoptosis inhibitory effect) on ophthalmic diseases or disorders, specifically retinal disorders, and thus can be effectively used as a pharmaceutical composition for preventing or treating PARP-1-related diseases, for example, ophthalmic diseases or disorders, which contains the same as an active ingredient.

  本发明涉及异喹啉酮衍生物、其制备方法以及用于预防或治疗与聚(ADP-核糖)聚合酶-1(PARP-1)有关的疾病的药物组合物，其中该异喹啉酮衍生物在纳摩尔单位浓度下表现出优异的PARP-1抑制作用，并在眼科疾病或障碍，特别是视网膜疾病方面表现出优异的细胞保护作用（凋亡抑制作用），因此可以有效地用作预防或治疗PARP-1相关疾病（例如眼科疾病或障碍）的药物组合物的活性成分。